Varenicline for Smoking Cessation: Mechanism of Action and Side Effects

Varenicline holds a unique position among pharmacological options for smoking cessation. In randomized controlled trials, it demonstrates the highest abstinence rates as a single agent compared to placebo, nicotine replacement therapy, and bupropion. For prescribing physicians, a detailed understanding of the mechanism of action, dosing schedule, side effect profile, and evidence base is essential to provide well-informed patient counseling and safe therapy management. This article provides a systematic overview of all clinically relevant aspects of varenicline – from the molecular level to clinical application.

Mechanism of Action at the Nicotinic Acetylcholine Receptor

To understand how varenicline works, it is worth taking a brief look at the neurobiology of nicotine dependence. In the central nervous system, nicotine primarily binds to α4β2 nicotinic acetylcholine receptors (nAChRs) in the mesolimbic dopamine system. This binding leads to dopamine release in the nucleus accumbens – the brain's central reward center. It is precisely this dopamine surge that produces the subjectively pleasant effect of smoking and represents the neurochemical core of addiction.

Varenicline is a partial agonist at the α4β2 nAChR. This means it binds to the same receptor as nicotine but activates it to only about 40–60% of the maximum nicotine effect. This results in two complementary therapeutic effects:

• Agonistic component: Through partial receptor activation, a moderate but clinically relevant dopamine increase is produced. This alleviates withdrawal symptoms such as dysphoria, irritability, difficulty concentrating, and craving. Patients experience smoking cessation as significantly less distressing.
• Antagonistic component: Since varenicline occupies the receptor, exogenously administered nicotine (from a smoked cigarette) can no longer fully activate the receptor. The familiar reward effect of smoking is absent or drastically reduced. Relapses thus become less "rewarding," and the conditioning between smoking and reward is weakened.

This dual mechanism of action – simultaneous reduction of withdrawal and blockade of the reward effect – makes varenicline particularly effective among available monotherapies. It also has some affinity for additional nAChR subtypes (α3β4, α6β2, α7), although their clinical relevance in the context of smoking cessation is less well characterized.

Pharmacokinetics at a Glance

Varenicline is almost completely absorbed after oral administration, with a bioavailability of approximately 90%. Peak plasma concentration is reached after 3–4 hours. The elimination half-life is approximately 24 hours, which justifies twice-daily dosing at steady state. The substance is predominantly excreted renally and largely unchanged. There are no relevant interactions via the cytochrome P450 system, which makes varenicline a comparatively uncomplicated substance in polypharmacy settings.

However, dose reduction is required in cases of impaired renal function (eGFR < 30 ml/min) – a point that is occasionally overlooked in clinical practice.

Dosing Schedule and Practical Application

The standard regimen follows a stepwise titration plan designed to improve tolerability. The quit date is typically set for day 8–14 after starting therapy, so that effective plasma levels are already present at the time of cessation.

Standard Dosing

Period	Dosage
Days 1–3	0.5 mg once daily
Days 4–7	0.5 mg twice daily
From day 8 (= quit date)	1 mg twice daily

The standard treatment duration is 12 weeks. If abstinence is achieved, an extension by an additional 12 weeks may be considered to reduce the risk of relapse. Studies show that such maintenance therapy significantly improves long-term abstinence.

Practical Tips for Prescribers

• Taking the medication with food and a full glass of water considerably reduces the common side effect of nausea.
• Flexible quit date planning: Some patients are unable to quit abruptly on day 8. A "gradual approach" – stepwise reduction of cigarette numbers over the first 12 weeks with a definitive quit at the end – has also been shown to be effective in studies and can be offered as an alternative.
• Combination with behavioral therapy or structured counseling substantially increases success rates. Varenicline alone is effective but reaches its full potential in a multimodal setting.
• Combination therapy with nicotine patches: The combination of varenicline plus nicotine patches has shown higher abstinence rates than varenicline alone in some studies. While the evidence is not yet fully consolidated, this approach may be considered in justified individual cases.

Side Effects and Their Management

As with any effective medication, varenicline has a relevant side effect profile. The good news: most side effects are dose-dependent, self-limiting, and manageable with simple measures.

Common Side Effects (≥ 1/10)

• Nausea – by far the most common side effect, affecting up to 30% of patients. Typically most pronounced during the first weeks, with a tendency toward spontaneous improvement. Taking the medication after meals and with adequate fluids are the most important countermeasures. If persistent, a temporary dose reduction to 0.5 mg twice daily may be considered.
• Sleep disturbances and abnormal dreams – vivid, intense, sometimes bizarre dreams are reported by approximately 10–15% of patients. Generally not dangerous but can be subjectively very distressing for some. Shifting the evening dose to the afternoon may help.
• Headaches – usually mild and transient.

Occasional Side Effects (≥ 1/100 to < 1/10)

• Flatulence, constipation, diarrhea
• Dry mouth, taste disturbances
• Increased appetite and weight gain
• Fatigue, dizziness
• Abdominal discomfort

Rare but Clinically Relevant Side Effects

• Skin reactions: Angioedema and severe skin reactions (Stevens-Johnson syndrome, erythema multiforme) have been described in isolated cases. Patients should be instructed to seek immediate medical advice if generalized skin changes occur.
• Cardiovascular events: See detailed discussion in the safety section.
• Seizures: Very rarely reported, including in patients with no history of seizures. In patients with known epilepsy, a careful risk-benefit assessment is required.

Neuropsychiatric Safety: What the Evidence Shows

The neuropsychiatric safety of varenicline was the subject of intense debate for years. Early post-marketing reports of suicidality, depression, agitation, and psychosis led to an FDA Boxed Warning and comparable warnings in Europe. These regulatory measures had a lasting impact on prescribing practices and caused considerable uncertainty among physicians and patients.

The EAGLES Study as a Turning Point

The EAGLES study (Evaluating Adverse Events in a Global Smoking Cessation Study) was the pivotal safety study demanded by regulatory authorities. This large-scale, randomized, double-blind, placebo-controlled, active-controlled multicenter trial enrolled over 8,000 participants – stratified by psychiatric history.

The key findings:

• No significantly increased risk of neuropsychiatric events with varenicline compared to placebo, nicotine patch, or bupropion – neither in the psychiatrically healthy nor in the psychiatric cohort.
• Varenicline was significantly more effective than placebo and nicotine patch in terms of abstinence rates in both cohorts.
• Based on these results, the FDA Boxed Warning was removed.

Clinical Implications

Despite the reassuring EAGLES data, clinically prudent vigilance remains appropriate:

• Patients with pre-existing psychiatric conditions (depression, bipolar disorder, schizophrenia, anxiety disorders) can be treated with varenicline but require closer monitoring – especially during the first weeks.
• Mood changes, agitation, new or worsening depressive symptoms, and suicidality should be communicated as potential warning signs. Patients and their families should be actively asked about these symptoms and encouraged to make immediate contact if they occur.
• Smoking cessation itself – regardless of the method chosen – can trigger neuropsychiatric symptoms. Nicotine withdrawal per se is associated with dysphoria, irritability, and depressed mood. A clear attribution of individual symptoms to the medication versus withdrawal is often difficult in individual cases.

Cardiovascular Safety

Early meta-analyses had postulated a possible association between varenicline and an increased risk of cardiovascular events (myocardial infarction, stroke, cardiovascular death). Here too, subsequent evidence has provided reassurance:

• Large cohort studies and the EAGLES study show no significantly increased cardiovascular risk with varenicline.
• In patients with pre-existing cardiovascular disease, the benefit of smoking cessation far outweighs the potential risk of the medication. Smoking remains by far the greatest modifiable cardiovascular risk factor.
• Nevertheless, documenting cardiovascular comorbidities and specifically asking about new-onset symptoms (chest pain, dyspnea, palpitations) is good clinical practice.

Contraindications and Special Patient Populations

Contraindications

• Hypersensitivity to the active substance or any excipients
• Severe renal impairment without dose adjustment

Pregnancy and Breastfeeding

Varenicline is not approved for use during pregnancy and breastfeeding. The available data are insufficient to make a safety statement. In pregnant smokers, behavioral therapy remains the first-line approach, supplemented by nicotine replacement therapy after individual risk-benefit assessment.

Adolescents Under 18 Years of Age

Varenicline is not approved for patients under 18 years of age. Available studies show no superior efficacy over placebo in this age group, with a comparable side effect profile.

Elderly Patients

In general, no dose adjustment is required provided renal function is adequate. Elderly patients benefit particularly from smoking cessation – even beyond age 65, quitting smoking significantly reduces mortality.

Patients with Renal Impairment

With an eGFR < 30 ml/min, the maximum dose is reduced to 0.5 mg twice daily. In end-stage renal disease requiring dialysis, varenicline is not recommended, as the substance is not sufficiently dialyzable.

Efficacy in Comparison: Positioning Within the Treatment Landscape

The efficacy of varenicline is supported by a robust body of evidence. Key comparative data at a glance:

• Varenicline vs. placebo: The odds ratio for continuous abstinence at 6–12 months is approximately 2.0–2.5. This translates to a doubling to tripling of the probability of quitting.
• Varenicline vs. bupropion: Varenicline consistently shows higher abstinence rates in head-to-head studies. The superiority is statistically significant and the effect difference clinically relevant.
• Varenicline vs. nicotine replacement therapy (NRT): Compared to NRT monotherapy (patch alone), varenicline is superior. Compared to combination NRT (e.g., patch plus gum/spray), the differences are smaller and in some analyses no longer significant.
• Varenicline plus NRT: The combination shows promising data and may represent the most effective available strategy – particularly for heavily dependent smokers.

Treatment Failure and Re-treatment

A failed quit attempt with varenicline is not a reason to avoid using the substance again. Studies show that re-treatment can be effective. What matters is an analysis of relapse triggers and, where appropriate, intensification of accompanying behavioral therapy.

Availability and Regulatory Aspects

The availability of varenicline (originally marketed under the brand name Champix®) was temporarily restricted due to contamination issues (detection of N-nitrosovarenicline above accepted limits) through a worldwide recall. In the meantime, both the original product and generics are available again in many markets. You should verify current availability in your region before prescribing.

Practical Recommendations for Prescribing Physicians

1. Assess motivation level: Varenicline is most effective in patients with clear motivation to quit. A brief motivational interview beforehand is worthwhile.
2. Educate about side effects: Transparently and proactively – especially regarding nausea and sleep disturbances. Many treatment discontinuations are preventable if patients know that the symptoms are transient.
3. Schedule follow-up appointments: At minimum during weeks 1–2 (quit date), week 4, and weeks 8–12. Telephone or digital contacts can meaningfully complement in-person visits.
4. Behavioral therapy support: Always recommend it. The combination of medication and behavioral intervention yields the best long-term outcomes.
5. Actively plan the quit date: Set a specific date, inform the social environment, identify triggers, and develop coping strategies.
6. Aftercare: Even after the end of the 12- to 24-week treatment course, the risk of relapse remains elevated. Regular follow-up in the subsequent months is advisable.

Practical Training

Smoking cessation is a complex field that equally requires pharmacological knowledge, motivational interviewing skills, and clinical experience. In the smoking cessation course by Simulation Tirol, you have the opportunity to work through the various treatment options – including varenicline – in a hands-on manner, practice counseling scenarios, and advance your training within an evidence-based, structured framework. Because as in many areas of medicine, theoretical knowledge only reaches its full potential through skilled practical application.

---